In neuroblastoma cells, retinoic acid induces cell cycle arrest and differentiation through degradation of the Fbox protein, Skp2, and stabilization of cyclin-dependent kinase inhibitor, p27. However, the mechanism responsible for retinoic acid-mediated Skp2 destabilization is unknown. Since Skp2 is degraded by anaphase-promoting complex (APC) Cdh1 , here we studied whether retinoic acid promotes differentiation of human SH-SY5Y neuroblastoma cells by modulating Cdh1. We found that retinoic acid induced the nuclear accumulation of Cdh1 that paralleled Skp2 destabilization and p27 accumulation. The mRNA and protein abundance of Rae1-a nuclear export factor that limits APC Cdh1 activity in mitosisdecreased upon retinoic acid-induced inhibition of neuroblastoma cell proliferation. Furthermore, either Rae1 overexpression or Cdh1 inhibition promoted Skp2 accumulation, p27 destabilization and prevented retinoic acidinduced cell cycle arrest and differentiation. Conversely, inhibition of Rae1 accelerated retinoic acid-induced differentiation. Thus, retinoic acid downregulates Rae1, hence facilitating APC Cdh1 -mediated Skp2 degradation leading to the arrest of cell cycle progression and neuroblastoma differentiation. Oncogene (2008) 27, 3339-3344; doi:10.1038/sj.onc.1210987; published online 21 January 2008 Keywords: retinoic acid; Rae1; Cdh1; Skp2; p27; neuroblastoma It is well established that the vitamin A metabolite, all-trans-retinoic acid (RA) plays important roles in the development of the mammalian nervous system, including neural patterning and development of cerebral structure (Maden, 2002; Clagett-Dame et al., 2006) . In certain neural progenitor niches of the postnatal brain, RA downregulates cellular proliferation and promotes neurogenesis (Matthay, 1999) , an observation that has raised the interest of RA in neurorepair strategies for some human neuroblastomas (Reynolds et al., 2003) . Although the underlying mechanism has not yet been elucidated, it is known that during neuroblastoma cell differentiation, RA induces cell cycle arrest in G 1 by accumulating the cyclin-dependent kinase (Cdk) inhibitor, p27 (Nakamura et al., 2003; Borriello et al., 2006) . The stability of p27 is known to be regulated by the E3 ubiquitin ligase SCF (Skp1/Cul1/F-box) activator, Skp2, which targets p27 for ubiquitination and proteasomal degradation during late G 1 (Sheaff et al., 1997; Carrano et al., 1999; Sutterluty et al., 1999; Bloom and Pagano, 2003) . Indeed, RA stabilizes p27 by enhancing proteasome-mediated degradation of Skp2 in several cancer cell lines (Dow et al., 2001; Nakamura et al., 2003; Zancai et al., 2005) , although the molecular mechanism is still unknown. Here we have investigated how Skp2 affects the expression of p27 during RAmediated SH-SY5Y neuroblastoma cell cycle arrest, and the underlying mechanism.
Cycling SH-SY5Y neuroblastoma cells were incubated with RA to induce cell cycle arrest and differentiation ( Figure 1 ). After 2-5 days, cells progressively developed phenotypic changes compatible with neuronal-like morphology characterized by neurite outgrowth (Encinas et al., 2000; Almeida et al., 2005; Lasorella et al., 2006; Figures 1a and b) . The expression of neuronal markers, Gap43, Map2 and Tau progressively increased up to 5 days of RA treatment (Figure 1c) , whereas the proportion of cells in S and G 2 /M phases decreased, and that in G 1 phase increased (Figure 1d ). In addition, proliferating cell nuclear antigen (PCNA) protein and retinoblastoma protein (pRb) phosphorylation decreased, whereas Cdk inhibitors p27 and p21 increased by RA treatment (Figure 1e ). Together, these results suggest that the SH-SY5Y neuroblastoma cell is an appropriate model to investigate the regulation of Skp2 during RA-induced cell cycle arrest and differentiation.
We first assessed whether Skp2 destabilization was necessary for RA-induced cell cycle arrest. Cycling SH-SY5Y cells profusely expressed Skp2 in both whole cell and nuclear extracts (Figures 1f and g ), but RA induced a Skp2, not Skp1, decrease (Figures 1f and g ), which coincided with p27 nuclear accumulation (Figure 1g ). Overexpression of full-length Skp2 cDNA (Figure 2a ), which revealed nuclear localization (Figure 2b ), increased the S phase and decreased the G 0 /G 1 phase in cycling cells, effects that were more pronounced by overexpressing a nondegradable Skp2 mutant lacking the destruction D-box (Skp2Ddb; Figure 2c ). These results suggest that Skp2 protein degradation is important for cell cycle arrest in SH-SY5Y neuroblastoma cells. In fact, Spk2Ddb, but not wild-type Skp2, overexpression strongly prevented RA-induced cell cycle exit, as assessed by 5-bromo-2-deoxyuridine (BrdU) staining (Figure 2d ), accumulation of p27 and Map2 (Figure 2e ), and neurite outgrowth ( Figure 2f ). These data are in good agreement with the recent work reporting p27 stabilization by proteasomedependent Skp2 degradation in cycling cancer cell lines (Zancai et al., 2005) .
Skp2 protein disappeared (Figure 1f ), but its mRNA remained (Figure 3a ) during the RA treatment of SH-SY5Y cells, suggesting a posttranscriptional regulation of Skp2 by RA. It has been described that Skp2-mediated p27 degradation is required for S-phase entry during the mitotic cell cycle . Conversely, during G 1 , Skp2 is destabilized, a process that is brought about by Cdh1-activated anaphasepromoting complex (APC), an E3 ubiquitin ligase that targets Skp2 for proteasomal degradation (Bashir et al., 2004; Wei et al., 2004) . Indeed, our results shown in Figures 2d and e confirm this notion in our cell model, since expression of Skp2Ddb mutant, refractory to Cdh1-mediated targeting, but not wild-type Skp2, prevented RA-induced p27 stabilization and cell cycle arrest in neuroblastoma cells. Previous data have reported that the APC activator Cdh1, but not Cdc20, is accumulated in postmitotic neurons (Gieffers et al., 1999; Almeida et al., 2005) . Here, we directly assessed the possible involvement of APC Cdh1 in RA-induced SH-SY5Y cell differentiation. As shown in Figure 3b , Cdh1 protein progressively accumulated in the nucleus, , 24 h before RA (10 mM) additions (Encinas et al., 2000; Almeida et al., 2005) . Neurite extension was measured using NIH Image 1.61 software. Western blotting was performed as described in Almeida et al. (2005) . Extracts were centrifuged at 600 g (5 min, 4 1C) for cytosolic (supernatant) and nuclear (pellet) fractioning. Nuclear fraction was further lysed for 2 h and clarified at 16 000 g for 30 min. Cell cycle distribution was measured by fluorescence-activated cell sorting analysis. Antibodies to PCNA (clone 24), p19
Skp1 (clone 52), pRb (clone G3-245), p27 Kip1 (clone G173-524) and p21 (clone SXM30) were from BD Pharmingen (BD Biosciences, Barcelona, Spain); p45
Skp2 antibody (clone SKP2-2B12) was purchased to Zymed (Invitrogen, CA, USA); glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody (clone 6C5) was from Ambion (Applied Biosystems, Austin, TX, USA); antibodies to Map2 (clone AP-20), Gap43 and Tau (1:2000) were from Sigma (Madrid, Spain).
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J Cuende et al while it disappeared from the cytosol during the RA treatment of SH-SY5Y cells. To investigate the role of Cdh1, we inhibited Cdh1 using RNA interference. Thus, expression of a Cdh1-specific shRNA (Almeida et al., 2005) in HEK293T cells caused efficient depletion of coexpressed wild-type Cdh1, but not a third-codon silent shRNA-refractory Cdh1 mutant ( Figure 3c) ; moreover, Cdh1 shRNA promoted Skp2 accumulation in cells coexpressing wild-type, but not the mutant Cdh1 form (Figure 3c ). In cycling SH-SY5Y cells, Cdh1 silencing promoted Skp2 and PCNA accumulation ( Figure 3d ) together with an increase in S phase and a decrease in G 0 /G 1 phase (Figure 3e ), in agreement with others (Bashir et al., 2004; Wei et al., 2004; Binne et al., 2007) . Furthermore, in RA-treated cells, Cdh1 silencing also triggered Skp2 accumulation, p27 destabilization ( Figure 3f ) and an increase in the percentage of cells in S phase (Figure 3g ), suggesting that these differentiating neuroblastoma cells are refractory to cell cycle exit. Indeed, only the green fluorescent protein (GFP) ( þ ) positive cells (which express Cdh1 shRNA) were negative for the neuronal marker, Map2, as confirmed by immunofluorescence (Figure 3h ). Inhibiting APC (Figure 3k ), resulting in S-phase entry (Figure 3l ). Together, these results strongly suggest that RA-induced neuroblastoma cell cycle arrest occurs via nuclear accumulation of Cdh1, which targets Skp2 for degradation and promotes p27 accumulation. Finally, we studied whether APC Cdh1 activity in RA-differentiated SH-SY5Y neuroblastoma cells was modulated by Rae1 and Nup98, that is, two nucleocytoplasmic factors involved in the downregulation of APC Cdh1 in early mitosis (Jeganathan et al., 2005) . Cells induced to differentiate with RA-promoted degradation of Rae1 protein, but not Nup98, and mRNA (Figures 4a  and b) , suggesting that RA downregulates Rae1 gene expression. Overexpression of Rae1 in cycling SH-SY5Y cells triggered Skp2 accumulation (Figure 4c ), increased the S phase and decreased G 0 /G 1 phase of the cell cycle (Figure 4d ). Moreover, in RA-treated cells, Rae1 overexpression prevented Skp2 degradation and p27 accumulation (Figure 4e ), resulting in S-phase entry , APC-BrdU Flow Kit, BD Biosciences). Overexpression of Skp2Ddb, but not Skp2, strongly prevented p27 stabilization, Map2 expression (e) and neurite outgrowth (f) in RA 3-day-treated SH-SY5Y cells. Immunocytochemistry was performed as described in Almeida et al. (2005) . After cells were fixed and permeabilized, they were incubated with anti-Skp2 (Zymed, 1:80 dilution) or anti-Map2 (Sigma, 1:100 dilution) overnight at 4 1C. Secondary antibody was anti-mouse-IgG-Cy3 (Sigma, 1:400 dilution). Cdh1 antibody (AR38) was a generous gift from Dr J Gannon (Clare Hall Laboratories, Cancer Research, UK). Lipofectamine 2000 (Invitrogen, Groningen, the Netherlands) was used for transfections. (Figure 4f ). Conversely, Rae1 silencing by siRNA in cycling SH-SY5Y cells triggered p27 accumulation (Figure 4g ) and increased the G 0 /G 1 phase of the cell cycle (Figure 4h) . Moreover, Rae1 siRNA accelerated RA-induced neuroblastoma differentiation, as judged by the increase in neurite extension (Figures 4i and j) and by the accumulation of Map2 and p27 (Figure 4k) . Together, these results suggest that RA triggers Rae1 downregulation, which seems to be important to ensure the degradation of the APC Cdh1 substrate, Skp2 and the accumulation of p27, leading to cell cycle arrest and differentiation in neuroblastoma cells.
In conclusion, here we show that Cdh1 accumulates in the nucleus of neuroblastoma cells induced to differentiate with RA; moreover, Cdh1 is required for the correct differentiation process because it keeps the . In (j) and (l) GFP þ cells represent those that were efficiency transfected with hEmi1. For Cdh1 shRNA experiments we used the 5 0 -TGAGAAGTCTCCCAGTCAG-3 0 (nt 235-253, accession number NM_016263) sequence, expressed as a shRNA (9-nt loop) from the pSupoer.neo/gfp vector (Oligoengine, Seatle, WA, USA) (Brummelkamp et al., 2002; Almeida et al., 2005) . The firefly luciferase 5 0 -CTGACGCGGAATACTTCGA-3 0 oligonucleotide (Ohtsuka et al., 2004) was used for control transfections.
Rae1 downregulation mediates neuroblastoma differentiation J Cuende et al nuclear levels of Skp2 protein low. In fully differentiated cells, such as postmitotic neurons, Cdc20 is not present and, hence, Cdh1 is critical to maintain the survival of these cells by degrading cyclin B1 (Almeida et al., 2005) , and to regulate axonal growth (Konishi et al., 2004) . Accordingly, APC Cdh1 activity in fully differentiated cells would be essential to prevent cell cycle re-entry. However, in proliferating neuroblastoma cells, we show here that APC Cdh1 activity would be also necessary to allow RA-induced cell cycle arrest and differentiation. Moreover, to maintain APC Cdh1 activity during this process, downregulation of Rae1 is a requisite. While fully understanding the mechanism whereby RA downregulates Rae1 requires further research, our results suggest an additional role for Rae1 in controlling the activity of APC Cdh1 as a molecular switch during the transition from proliferation to differentiation. (f) Expression of Rae1 increased the proportion of S phase (BrdU staining) in SH-SY5Y cells treated with RA (3 days). Rae1 silencing induced p27 accumulation (g) and cell cycle arrest (h) in G 0 /G 1 in cycling SH-SY5Y cells. Expression of Rae1 siRNA in cycling SH-SY5Y promoted neurite outgrowth (i, j), Map2 expression and p27 stabilization (k) after 2 days of RA treatment. In (d) and (f) green fluorescent protein (GFP þ ) cells represent those that were efficiency transfected with Rae1. *Po0.05 versus control. Rae1 antibody was from Abcam (Cambridge, UK), and the antibody to Nup98 from Cell Signalling (Danvers, MA, USA). Rae1 full-length cDNA (IMAGE:40032942) was purchased from Geneservice and subcloned into BamHI and XhoI sites of pcDNA3.1( þ ). pcDNA3.1( þ ) encoding Rae1 was cotransfected with GFP-expressing vector peGFPC2 to allow flow cytometric analysis. For Rae1 siRNA experiments, we used the GCAGUAACCAAGCGAUACA sequence (Blower et al., 2005) , using a firefly luciferase siRNA sequence (CUGACGCGGAAUACUUCGA) as a control (Dharmacon, Lafayette, IN, USA).
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